Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine, as global R&D investment approaches $360 billion ...

The field of biotechnology has always transformed cutting-edge science into life-changing medicines, but today that transformation is happening at a staggering pace.

Even newer “minimally invasive” ideas, like stent-mounted electrodes deployed through blood vessels, still require a catheter ...

Neuralink Might Let You Control Game Characters�The Future of Gaming and Its Potential! ​​​Stimulus check update: Trump ...

One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the ...

The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience. BY Mike Finelli The way we ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

Puma Biotechnology has one approved drug, strong cash, and is developing alisertib with key ALISCA trial readouts in 1H 2026.